Renee Gaeta Joins Outset Medical as Chief Financial Officer

Outset Medical Inc. has appointed Renee Gaeta as chief financial officer (CFO), succeeding Nabeel Ahmed. She will lead the company’s Finance and Information Technology and Human Resources departments.

“Renee brings deep financial and leadership experience to Outset with a proven track record from her roles at publicly traded medical-device growth companies as both a CFO and board member,” Outset Medical Chair/CEO Leslie Trigg said. “She is the ideal fit for Outset as we drive our next phase of growth and our goal to achieve near-term profitability. I want to thank Nabeel for his contributions to Outset and wish him well in his future endeavors.”

With the change in CFO leadership, Outset reiterated its 2025 financial guidance, including expected revenue of $115 million to $125 million and non-GAAP gross margin in the high 30% range.

Gaeta most recently served as CFO of Shockwave Medical until its $13 billion acquisition by Johnson and Johnson MedTech last May. She was previously CFO at Eko Health, where she also led both finance and human resources, and Establishment Labs, where she played a key role in the company’s initial public offering and growing the global business. Gaeta has served as a member of the Board of Directors and the audit committee of Candel Therapeutics since August 2022 and was previously audit committee chair and a board director of SeaSpine Holdings from 2019 until its acquisition in 2023 by Orthofix Medical.

Gaeta earned a bachelor of science degree cum laude, in accounting from Loyola Marymount University and is a certified public accountant in California.

“Outset is transforming dialysis care, and I am honored to join the company as its next CFO,” Gaeta stated. “Tablo offers clear and compelling clinical, financial and operational value to acute, post-acute and home dialysis providers. I look forward to playing an important role in helping drive Outset to achieve its growth and profitability goals.”

Outset is pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, cleared by the U.S. Food and Drug Administration for use from the hospital to the home, strives to transform the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with two-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical Inc.